Federal workers get drug-cost transparency; PBMs lose hidden rebate profits
H.R. 6610 — Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] · Filed by Jake Auchincloss (D-MA) · 42 cosponsors · Introduced Dec 11, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires pharmacy benefits managers (PBMs) administering drug benefits for federal employees to reimburse in-network pharmacies based on actual drug acquisition costs plus a small markup, pay state-level dispensing fees, pass manufacturer rebates to patients at point of sale, and prohibits PBMs from steering patients to affiliated pharmacies or restricting which pharmacies can fill prescriptions. The bill imposes civil penalties up to $10,000 per violation (capped at $100,000 per PBM per carrier per decade) and can debar PBMs after 10 violations, with enforcement by the Office of Personnel Management.
Why we flagged it
The bill's operative mechanism is a comprehensive reimbursement and conduct standard for pharmacy benefits managers in the federal employee health plan, designed to reduce hidden markups, eliminate steering incentives, and mandate rebate pass-through. It is regulatory reform, not a commemorative or appropriations measure.
What the text implies
- Mandatory rebate pass-through at point of sale may reduce PBM revenue from rebate arbitrage, potentially shifting PBM business models toward transparent service fees rather than hidden spread capture.
- Prohibition on affiliate steering and network restrictions may increase generic and independent pharmacy utilization, reducing captive-market dynamics that favor large retail chains.
The full analysis lists 5 implications of this text.
Who stands to gain
independent pharmacies; regional pharmacy chains; federal employees and retirees (via lower copays and coinsurance)